Fe-mn-igf-amd nanoparticles

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Animals1

Outcomes

Oxidative stress and ROS signalling

downin animals1

1 study

Fe-mn-igf-amd nanoparticles decrease oxidative stress and ROS signalling.
“reduction of reactive oxygen species”
Animalsliver cirrhosisliver
Fe-Mn-IGF-AMD nanoparticles in accurate detection and treatment of liver cirrhosis via regulating relaxation coefficients and attenuating hepatocyte senescence
Colloids and surfaces. B, Biointerfaces8 Oct 2025

More on Oxidative stress and ROS signalling

Cellular senescence

downin animals1

1 study

Fe-mn-igf-amd nanoparticles decrease cellular senescence.
“attenuation of hepatocyte senescence”
Animalsliver cirrhosisliver
Fe-Mn-IGF-AMD nanoparticles in accurate detection and treatment of liver cirrhosis via regulating relaxation coefficients and attenuating hepatocyte senescence
Colloids and surfaces. B, Biointerfaces8 Oct 2025

Latest

Colloids and Surfaces B, Biointerfaces15 Oct